Nutriband Inc (NTRB) - Total Liabilities
Based on the latest financial reports, Nutriband Inc (NTRB) has total liabilities worth $870.21K USD as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Nutriband Inc operating cash flow efficiency to assess how effectively this company generates cash.
Nutriband Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Nutriband Inc's total liabilities have evolved over time, based on quarterly financial data. Check Nutriband Inc (NTRB) asset resilience to evaluate the company's liquid asset resilience ratio.
Nutriband Inc Competitors by Total Liabilities
The table below lists competitors of Nutriband Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Visi Media Asia Tbk
JK:VIVA
|
Indonesia | Rp6.12 Trillion |
|
Wolford Aktiengesellschaft
VI:WOL
|
Austria | €184.55 Million |
|
Plastiblends India Limited
NSE:PLASTIBLEN
|
India | Rs906.56 Million |
|
Perusahaan Sadur Timah Malaysia Perstima Bhd
KLSE:5436
|
Malaysia | RM493.74 Million |
|
SolTech Energy Sweden AB
ST:SOLT
|
Sweden | Skr1.41 Billion |
|
Topmix Berhad
KLSE:0302
|
Malaysia | RM35.50 Million |
|
DiGiSPICE Technologies Limited
NSE:DIGISPICE
|
India | Rs4.98 Billion |
|
Madusari Murni Indah Tbk PT
JK:MOLI
|
Indonesia | Rp421.88 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Nutriband Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NTRB company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nutriband Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nutriband Inc (2016–2025)
The table below shows the annual total liabilities of Nutriband Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-01-31 | $1.04 Million | -3.51% |
| 2024-01-31 | $1.08 Million | +22.13% |
| 2023-01-31 | $883.39K | +0.34% |
| 2022-01-31 | $880.38K | -68.73% |
| 2021-01-31 | $2.82 Million | +39.22% |
| 2020-01-31 | $2.02 Million | +401.81% |
| 2019-01-31 | $403.01K | +828.78% |
| 2018-01-31 | $43.39K | +196.83% |
| 2017-01-31 | $14.62K | +23.88% |
| 2016-01-31 | $11.80K | -- |
About Nutriband Inc
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA b… Read more